- Home
- CHY vs AKBA Comparison
CHY vs AKBA Comparison
Compare CHY & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- AKBA
- Stock Information
- Founded
- CHY 2003
- AKBA 2007
- Country
- CHY United States
- AKBA United States
- Employees
- CHY N/A
- AKBA N/A
- Industry
- CHY Investment Managers
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- AKBA Health Care
- Exchange
- CHY Nasdaq
- AKBA Nasdaq
- Market Cap
- CHY 839.8M
- AKBA 861.7M
- IPO Year
- CHY N/A
- AKBA 2014
- Fundamental
- Price
- CHY $11.18
- AKBA $2.96
- Analyst Decision
- CHY
- AKBA Strong Buy
- Analyst Count
- CHY 0
- AKBA 5
- Target Price
- CHY N/A
- AKBA $6.90
- AVG Volume (30 Days)
- CHY 128.3K
- AKBA 3.9M
- Earning Date
- CHY 01-01-0001
- AKBA 11-06-2025
- Dividend Yield
- CHY 10.11%
- AKBA N/A
- EPS Growth
- CHY N/A
- AKBA N/A
- EPS
- CHY N/A
- AKBA N/A
- Revenue
- CHY N/A
- AKBA $203,733,000.00
- Revenue This Year
- CHY N/A
- AKBA $38.23
- Revenue Next Year
- CHY N/A
- AKBA $38.17
- P/E Ratio
- CHY N/A
- AKBA N/A
- Revenue Growth
- CHY N/A
- AKBA 16.75
- 52 Week Low
- CHY $9.97
- AKBA $1.24
- 52 Week High
- CHY $12.16
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- CHY 65.13
- AKBA 40.51
- Support Level
- CHY $10.80
- AKBA $2.92
- Resistance Level
- CHY $11.25
- AKBA $3.15
- Average True Range (ATR)
- CHY 0.09
- AKBA 0.14
- MACD
- CHY 0.03
- AKBA 0.01
- Stochastic Oscillator
- CHY 84.44
- AKBA 18.75
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.